Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

NCT02586857 is registered in ClinicalTrials.gov with Acerta Pharma BV as lead sponsor.

NCT NCT02586857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02586857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Lead sponsor
Acerta Pharma BV
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 25, 2016
Completion date
April 1, 2026
Enrollment
24 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme